Recurrent Non-small Cell Lung Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionTreatment
NCT00088959Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment
NCT01839955Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung CancerTreatment